|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Clinical Solutions |
|---|---|
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002167 |
Purpose
To determine the objective tumor response and remission rate of AIDS-related Kaposi's sarcomas (KS) following a single dose of tin ethyl etiopurpurin (SnET2) followed by photodynamic therapy (PDT). To determine the systemic and local toxicity, and morbidity safety profile of SnET2-PDT.
| Condition | Intervention | Phase |
|---|---|---|
|
Sarcoma, Kaposi HIV Infections |
Drug: Tin ethyl etiopurpurin |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Parallel Assignment, Safety Study |
| Official Title: | Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Patients with the following prior conditions are excluded:
Excluded within 7 days of therapy:
Excluded within 3 months of therapy:
Excluded within 6 months of therapy:
Prior Medication:
Excluded:
Prior Treatment:
Excluded within 3 months prior to therapy:
Contacts and Locations| United States, California | |
| Cedars Sinai Med Ctr | |
| Los Angeles, California, United States, 90048 | |
| Univ of California / San Francisco / Dermatology | |
| San Francisco, California, United States, 94143 | |
| Univ of Southern California / Los Angeles | |
| Los Angeles, California, United States, 90033 | |
| United States, Colorado | |
| Health One - Rocky Mountain Cancer Ctr | |
| Denver, Colorado, United States, 80218 | |
| United States, New York | |
| Buffalo Gen Hosp / PDT Ctr | |
| Buffalo, New York, United States, 14203 | |
| United States, Tennessee | |
| Thompson Cancer Survival Ctr | |
| Knoxville, Tennessee, United States, 37916 | |
More Information
| Study ID Numbers: | 261A |
| Study First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00002167 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Skin Neoplasms Sarcoma, Kaposi Acquired Immunodeficiency Syndrome |
Photochemotherapy tin etiopurpurin Radiation-Sensitizing Agents |
|
Sexually Transmitted Diseases, Viral Acquired Immunodeficiency Syndrome Sarcoma, Kaposi Skin Neoplasms Immunologic Deficiency Syndromes Kaposi Sarcoma Herpesviridae Infections Virus Diseases Neoplasms, Connective and Soft Tissue Photosensitizing Agents |
Soft Tissue Sarcomas Malignant Mesenchymal Tumor Radiation-Sensitizing Agents HIV Infections Sexually Transmitted Diseases Sarcoma DNA Virus Infections Retroviridae Infections Tin etiopurpurin |
|
Sexually Transmitted Diseases, Viral Slow Virus Diseases Physiological Effects of Drugs Infection Neoplasms, Connective and Soft Tissue Therapeutic Uses Neoplasms, Vascular Tissue Dermatologic Agents Retroviridae Infections Tin etiopurpurin RNA Virus Infections Neoplasms by Histologic Type Immune System Diseases Sarcoma, Kaposi |
Acquired Immunodeficiency Syndrome Immunologic Deficiency Syndromes Pharmacologic Actions Herpesviridae Infections Virus Diseases Neoplasms Photosensitizing Agents Radiation-Sensitizing Agents HIV Infections Sexually Transmitted Diseases Lentivirus Infections Sarcoma DNA Virus Infections |